周彩存晚期非小细胞肺癌的准治疗 ppt课件.pptx

周彩存;晚期非小细胞肺癌的精准治疗;;;Precision Medicine in Advanced NSCLC;US Lung Cancer Mutational Consortium (LCMC);LCMC: Benefit in overall survival for personalized treatment;IPASS开启了EGFR-TKI的肺癌精准医学时代;九项临床研究验证TKI是EGFR突变阳性患者一线治疗的最佳选择;NCCN指南明确单药TKI是目前EGFR突变阳性患者标准治疗;阿法替尼 40mg/天*;LUX-Lung 7: PFS (独立评估);AZD9291用于经治T790M+的NSCLC： AURA2 ( II期研究 );AURA17研究：AZD9291 中国注册临床研究;AZD9291一线治疗EGFR突变NSCLC数据令人期待;AZD9291，对比吉非替尼或厄洛替尼治疗EGFR-TKI敏感突变的初治晚期NSCLC的随机III期临床研究(FLAURA);2016年ASCO公布肺癌最新液态活检数据（II/II）;Slide 8;Phase III trials comparing crizotinib with chemotherapy in br /ALK+ lung cancer (PROFILE 1007 and 1014);Limitations of crizotinib;J-ALEX: Study Design;Primary Endpoint: PFS by IRF (ITT Population);Efficacy results for ALK+ patients;如何优化？;Precision Medicine in Advanced NSCLC;E4599：贝伐珠单抗一线联合卡铂/紫杉醇显著延长PFS、OS及ORR;BEYOND：贝伐珠单抗在中国人群疗效的验证;BEYOND：贝伐珠单抗联合卡铂/紫杉醇显著延长PFS及OS;Precision Medicine in Advanced NSCLC;Activity in pretreated patients;Nivolumab vs docetaxel in advanced NSCLCOverall survival;Pembrolizumab (2 or 10 mg/kg) versus docetaxel in advanced NSCLC: Overall SurvivalHerbst R et al. Lancet Oncology 2015, online December 18;Slide 16;Slide 17;一线策略？;Primary endpoint: Progression-free survival (independent radiology review committee) in patients with strongly PD-L1 positive tumors;;;;;;;;34% of Patients were TPS＜1%;KEYNOTE-021(phase Ⅰ/Ⅱ):study design;;KEYNOTE-021: OS;;;;;;;CheckMate 012 Study Design: Nivolumab Plus Ipilimumab in First-line NSCLC;;;;;;;;JVDF：Ram联合Pembro I期试验;JVDF：NSCLC患者安全性;JVDF：NSCLC患者疗效;结论;谢谢